{'fraction_non_alphanumeric': 0.05805609915198956, 'fraction_numerical': 0.04044357469015003, 'mean_word_length': 4.745318352059925, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 1, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The Influence of Polymorphism at Position 16 of the β2-Adrenoceptor on the Development of Tolerance to β-Agonist

Polymorphism at position 16 of the β2-adrenoceptor alters receptor down-regulation in vitro. Our aim was to compare the development of tolerance to (3-agonist in homozygous Gly-16 patients with patients harboring the “wild” genotype (homozygous Arg-16) during regular treatment with salmeterol. In a prospective, randomized, double blind, placebo controlled, cross over study, 20 subjects with mild to moderate asthma (10 Gly-16, 10 Arg-16) received 2 weeks of treatment with inhaled salmeterol 100 μg b.i.d. Thereafter, dose responses to inhaled salbutamol were constructed for forced expiratory volume in 1 sec (FEV1), heart rate, QTc interval, serum potassium and glucose, and finger tremor. The protective effect of salbutamol against adenosine monophosphate (AMP) challenge was also measured. Salmeterol resulted in a significant reduction in the area under curve (AUC) for FEV1 (p = 0.01), heart rate (p = 0.01), QTc interval (p = 0.01), and tremor (p = 0.05), and in the maximum responses for FEV1 (p = 0.05), heart rate (p = 0.02), and glucose (p = 0.02). The protective effect of salbutamol against AMP was reduced by 3.61 doubling doses (p < 0.001). However, differences between Gly-16 and Arg-16 patients were small and nonsignificant. Thus, although tolerance is influenced in vitro by polymorphism of the β2-adrenoceptor, the magnitude of between genotype differences in vivo is unlikely to be significant.